RxDoctor Payments Data

Jeffrey Puglisi, MD

Internal Medicine · Greenwich, CTNPI 1376539213

Payments from drug & device makers

$1,416in general payments, 2019–2025

Across 63 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$182
  • Abbott$178
  • Pfizer$137
  • GSK$134
  • Amgen$89
  • Esperion Therapeutics, Inc.$83
  • plus $612 from 17 others

What the payments were for

  • Food & beverage$1,416100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,416 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$43,618
Medicare patients
111
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$29,708
Dexlansoprazole DrDexlansoprazole11$4,865
Rosuvastatin Calcium139$2,207
Atorvastatin Calcium115$1,806
Potassium Chloride37$810
Losartan Potassium49$697
Ezetimibe32$687
Olmesartan Medoxomil18$598
Amlodipine Besylate52$518
Zolpidem Tartrate43$470
Lorazepam24$340
Levothyroxine Sodium37$332
Doxycycline Hyclate14$321
Azithromycin19$303
Carvedilol15$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$29,70836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Greenwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →